Groop L, Eriksson C J, Huupponen R, Ylikahri R, Pelkonen R
Diabetologia. 1984 Jan;26(1):34-8. doi: 10.1007/BF00252260.
The value and reproducibility of the chlorpropamide-alcohol flush (CPAF) have been questioned, and objective measures of the test are required. Recording of facial skin temperature, measurement of chlorpropamide, ethanol and acetaldehyde concentrations have been proposed for this purpose. The present study was designed to evaluate the relative contributions of these variables in determining CPAF. Twenty-one Type 2 (non-insulin-dependent) diabetic patients (11 CPAF-positive and 10 CPAF-negative according to previous tests with standard amounts of alcohol and chlorpropamide) were investigated in a random fashion with either chlorpropamide or placebo given on three subsequent evenings before a two-step alcohol challenge with increasing body-weight-matched amounts of alcohol. Higher rises in facial skin temperature and heart rate, higher flush-score and higher acetaldehyde levels resulted from chlorpropamide therapy than followed placebo. After smaller alcohol challenges (with chlorpropamide pretreatment) there were positive intercorrelations between flush-score, rise in facial skin temperature, and plasma concentrations of chlorpropamide and blood acetaldehyde. The increased alcohol dose abolished most of these correlations and a minimum temperature rise of 1.8 degrees C appeared in all but two subjects regardless of previous CPAF classification. During the current experimental conditions, the previously-classified CPAF-positive and CPAF-negative patients did not differ with respect to flush-score, rise in skin temperature, heart rate, blood acetaldehyde or ethanol concentrations, whereas they differed with respect to chlorpropamide concentrations. The present results support the view that CPAF is associated with elevated blood acetaldehyde levels due to inhibition of aldehyde dehydrogenase by chlorpropamide.(ABSTRACT TRUNCATED AT 250 WORDS)
氯磺丙脲-酒精潮红反应(CPAF)的价值及可重复性受到质疑,因此需要对该测试进行客观测量。为此,有人提出记录面部皮肤温度、测量氯磺丙脲、乙醇和乙醛浓度。本研究旨在评估这些变量在确定CPAF中的相对作用。对21例2型(非胰岛素依赖型)糖尿病患者(根据之前使用标准量酒精和氯磺丙脲的测试,11例CPAF阳性,10例CPAF阴性)进行随机研究,在连续三个晚上给予氯磺丙脲或安慰剂,然后进行两步酒精激发试验,酒精量与体重匹配且逐渐增加。与安慰剂相比,氯磺丙脲治疗导致面部皮肤温度和心率升高幅度更大、潮红评分更高、乙醛水平更高。在较小剂量酒精激发试验(氯磺丙脲预处理)后,潮红评分、面部皮肤温度升高与氯磺丙脲血浆浓度和血液乙醛之间存在正相关。增加酒精剂量消除了大部分这些相关性,除两名受试者外,所有受试者无论之前的CPAF分类如何,最低温度升高均为1.8摄氏度。在当前实验条件下,之前分类的CPAF阳性和CPAF阴性患者在潮红评分、皮肤温度升高、心率、血液乙醛或乙醇浓度方面没有差异,而在氯磺丙脲浓度方面存在差异。目前的结果支持这样一种观点,即CPAF与氯磺丙脲抑制醛脱氢酶导致血液乙醛水平升高有关。(摘要截短至250字)